Investor Presentaiton
Leveraging precision medicine to improve outcomes for patients
WELIREG
MK-10841
MK-3543
Presented data at ESMO from
Phase 3 LITESPARK-005 study
for treatment of adults with
previously treated advanced
RCC, which showed statistically
significant and clinically
meaningful improvement in
progression-free survival vs.
everolimus (standard of care)
• FDA granted priority review
with target action date of
January 17th
Proceeding with additional
Phase 3 studies
•
Presented data at ESMO for
oral KRAS inhibitor as
monotherapy in solid tumors
and in combination with
KEYTRUDA in patients with
metastatic NSCLC whose
tumors harbored KRAS G12C
mutations
•
Began enrolling patients in
Phase 3 study evaluating
bomedemstat (LSD1 inhibitor) in
2L essential thrombocythemia
1. In collaboration with Taiho and Astex
MERCK 23View entire presentation